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Abstract: Background: Current diagnosis and staging of advanced epithelial ovarian cancer (aEOC) 
has important limitations and better biomarkers are needed. We investigate the performance of non-
haematopoietic circulating cells (CCs) at the time of disease presentation and relapse. Methods: 
Venous blood was collected prospectively from 37 aEOC patients and 39 volunteers. CCs were 
evaluated using ImageStream TechnologyTM and specific antibodies to differentiate epithelial cells 
from haematopoetic cells. qRT-PCR from whole blood of relapsed aEOC patients was carried out 
for biomarker discovery. Results: Significant numbers of CCs (CK+/WT1+/CD45−) were identified, 
quantified and characterised from aEOC patients compared to volunteers. CCs are abundant in 
women with newly diagnosed aEOC, prior to any treatment. Evaluation of RNA from the CCs in 
relapsed aEOC patients (n = 5) against a 79-gene panel revealed several differentially expressed 
genes compared to volunteers (n = 14). Size differentiation of CCs versus CD45+ haematopoietic cells 
was not reliable. Conclusion: CCs of non-haematopoetic origin are prevalent, particularly in 
patients with newly diagnosed aEOC. Exploiting a CC-rich population in aEOC patients offers 
insights into a part of the circulating microenvironment. 
Keywords: advanced epithelial ovarian cancer; circulating tumour cells; circulating endothelial cells 
 
1. Introduction 
Detection of potentially small populations of non-haematopoetic circulating tumour cells (CTCs) 
within whole blood in cancer patients represents a significant technical challenge [1,2]. Isolating CTCs 
is generally attempted by using physical features such as size and enrichment techniques to confirm 
the identity of epithelial rather than haematopoietic cells. This has relied on surface proteins such as 
the Epithelial Cell Adhesion Molecule (EpCAM) to confirm/refute their origin as cancer cells. 
The most widely used method for CTC analysis is the CELLSEARCH® CTC Test, FDA approved 
in breast, colorectal and prostate cancer, where identification of CTCs broadly rely on EpCAM, 
despite evidence of considerable heterogeneity of EpCAM expression during the cell cycle, in 
different cell lines and a lack of EpCAM in cells undergoing epithelial-mesenchymal transition 
(EMT)[3–5]. The CellSearch test has been explored in patients with ovarian cancer in multiple 
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publications with very low yields (e.g., single CTCs in 7.5 mL of whole blood, which may contain 75 
million leucocytes and 50 billion erythrocytes) and is thus of limited utility [6] even in patients with 
recently diagnosed advanced epithelial ovarian cancer (aEOC) prior to any treatment. Most groups 
have used EpCAM as the common key target/antigen for the identification and confirmation of 
epithelial origin, with or without numerous other epithelial markers such as MUC1, MUC16, CK8, 
CK18, CK19, CA125, DPP4, ERCC1, HER2, MOC-31, PPIC. In clinical practice, 
immunohistochemistry assays on tissue likely to be of ovarian/fallopian tube/primary peritoneal 
origin utilise different antigens such as CK7, CK20 and WT1 to confirm the diagnosis of high-grade 
serous cancer prior to definitive treatment. We sought to explore the use of these antigens to identify 
CCs in aEOC patients. 
The primary aim of this study was to examine whole blood of patients with aEOC using 
ImageStream™ (Amnis), a high-definition circulating cell (HD-CC) imaging flow cytometry system, 
without using surface protein-based enrichment techniques. This technology allows multiple 
antibody applications and presents CCs in sufficient definition to satisfy diagnostic pathology image 
quality requirements [7,8]. Clinical immunohistochemistry cell surface and nuclear 
immunohistochemical antibody markers, initially pan-cytokeratin (PCK; AE1/AE3), CD45, and 
DRAQ5™ were used to identify and characterise non-haematopoetic and haematopoetic cells. 
Subsequently WT1 antibody was used to specifically identify cells of high grade serous (ovarian, 
fallopian tube/primary peritoneal) origin. Correlations were made with serum CA125 levels during 
treatment and CC levels in 4 patients. We have expanded on our observations, to include further 
interrogation of some liquid biopsies by means of gene expression from whole blood. 
2. Materials and Methods 
2.1. Cell Culture 
SKOV3 and MDAH-2774 ovarian cancer cells (ATCC) were grown in DMEM (Dulbecco’s 
Modified Eagle’s Medium, Gibco, Paisley, UK) supplemented with 10% FBS (fetal bovine serum, 
Gibco), 1% penicillin/streptomycin (Gibco) and 1% L-glutamine (Gibco); at 37 °C/5% CO2. PEO1 cells 
were grown in RPMI-1640, 10% FBS, 1% penicillin/streptomycin at 37 °C/5% CO2. 
Healthy volunteer (control) whole blood (1mL) was spiked individually with 2 cell lines, SKOV3 
and MDAH-2774, to mimic liquid biopsies that were processed as before and analysed using the 
enumeration features of the ImageStream™ based on size criteria and staining for both EpCAM and 
pan-cytokeratin (AE1/AE3) antibodies. This procedure was repeated with the introduction of 
different quantities of SKOV3 and MDAH-2774 cells, to assess the efficiency of cell retrieval and loss 
when using EpCAM and AE1/AE3 markers. The cell suspension was resuspended in different 
volumes to give a variety of cell concentrations between 20–200,000 cells/mL and spiked in 1mL blood 
from a donor. 
2.2. Patients 
Patients and healthy volunteers included in this report were enrolled in the prospective 
CICATRIx clinical study where blood samples are collected from healthy volunteers and patients 
with advanced cancer attending Mount Vernon Cancer Centre (East and North Hertfordshire NHS 
Trust) for exploratory biomarkers. All volunteers and patients provided written informed consent 
for participation in the study and for use of their donated tissue (patients only) and blood specimens. 
The CICATRIx study: Sample collection study to explore circulating tumour cells, cell free DNA 
and leucocytes with ImageStream analysis in patients with various cancers. Protocol number 
RD2016-08 was approved by the West Midlands–South Birmingham Ethics Committee (reference 
16/WM/0196). 
TRANS-METROBIBF: Sample collection study to investigate the predictive role of Circulating 
Tumour Cells (CTCs) and their gene expression in relation to outcome in multiply-relapsed ovarian 
cancer patients. Protocol number: RD2013-01 was approved by the South East Coast–Surrey Ethics 
Committee (reference 14/LO/0792). 
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The studies were performed in accordance with the Declaration of Helsinki. 
5–10 mL of whole blood was taken from patients at regular intervals with a tissue diagnosis of 
high-grade serous ovarian cancer (HGSOC), in one of the three groups: 
(1) Relapse—patients whose aEOC had relapsed following prior remission, and who required 
further chemotherapy treatment. 
(2) NACT—patients whose primary treatment at diagnosis was Neo-Adjuvant Chemotherapy. 
(3) post-PDS—patients who had had Primary Debulking Surgery as their first treatment for 
aEOC. 
39 healthy female volunteers donated 5–10 mL whole blood, which was also screened for cells 
that would stain with pan-cytokeratin and WT1 antibodies. Whole blood samples were assayed 
within 6 days of venesection. 
2.3. Clinical Cohorts 
Three cohorts of patients with aEOC were included in this exploration of CCs (Figure 1): 
(1) In the Relapse cohort, patient samples were taken prior to the first infusion of the course of 
chemotherapy and at the time of subsequent infusions. This group included 5 patients who 
participated in the METRO-BIBF clinical trial, a phase II, randomised, placebo-controlled, 
multicentre, feasibility study of low dose (metronomic) cyclophosphamide with and without 
nintedanib (BIBF 1120)/placebo (all patients received oral cyclophosphamide). Bloods tests were 
performed every 6 weeks at clinic review in the METRO-BIBF patients and their samples assayed for 
pan-cytokeratin, DRAQ5™ and CD45, but not WT1 expression. All other relapsed patients had WT1 
expression examined. 
(2) In the NACT cohort, patient samples were taken following confirmed histological diagnosis 
and prior to the start of their chemotherapy and at each subsequent treatment. Many of these patients 
underwent interval surgery following 3–4 chemotherapy cycles. 
(3) In the post-PDS cohort, patient samples were taken after surgery and prior to any adjuvant 
chemotherapy and at each subsequent chemotherapy cycle. 
 
Figure 1. Details of patients enlisted in the study. (A) Neoadjuvant chemotherapy and interval 
surgery; NACT cohort (n = 13) and Primary surgery, PDS cohort (n = 9); (B) Relapse treatment aEOC 
patients (n = 15). 
Initially, a comparative assessment was made of a single sample, 30 mL from each of four 
patients, decanted into 6–7 individual tubes of different types: EDTA, Cell-Free DNA Blood 
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Collection Tube (Streck), PAXgene Blood DNA Tube (Qiagen), and Cell-Free DNA Collection Tube 
(Roche) to establish the best vehicle for cell preservation prior to assay. Samples were analysed within 
4 hours of venesection for Day 1 and then daily for a further 6 days to assess the preservation ability 
of each type of collection tube. Subsequent patient and “control” samples from volunteers were 
collected in Roche tubes and assayed within 6 days of venesection. 
2.4. CA125 Measurements 
Serum CA125 assays were done for all aEOC patients, as part of standard practice, i.e., 
approximately each time they had chemotherapy treatment. 
2.5. Preparing Blood Samples for Imagestream™ 
One ml of whole blood from each patient was decanted from Roche tubes into a 15 mL Falcon 
tube and mixed with 9 mL of red blood cell (RBC) lysis buffer (G Biosciences), inverted 10 times and 
incubated for 10 min with gentle agitation. The solution was then centrifuged at 2500 RPM for 10 
min, the supernatant removed and a further 3 mL of RBC lysis buffer added to resuspend the pellet, 
before being incubated for 10 min at room temperature with gentle agitation. The solution was spun 
for a further 10 minutes at 2500 RPM, and the supernatant was aspirated. The pellet was then washed 
in 1.5 mL of PBS, and the resulting suspension was moved to a 1.5 mL microcentrifuge tube and spun 
at 3600 RPM for 3 min. Samples were then fixed immediately. 
2.6. Fixing Cells 
Cell pellets were transferred to a 1.5 mL microcentrifuge tube and resuspended in 1mL of ice 
cold 4% paraformaldehyde (PFA, Sigma, Gillingham, UK) for 7 min. The cell suspension was 
centrifuged for 2 min at 3600 RPM and the PFA was removed. Cells were washed in prewarmed PBS 
twice, centrifuging for 2 min at 3600 RPM between each wash. After the cells were fixed and washed 
with PBS, the pellet was suspended in 0.5% Triton X in PBS (v/v) and incubated on ice for 10 min, 
followed by centrifugation at 3600 RPM for 3 min to enable membrane permeabilisation for 
cytoplasmic/nuclear staining. 
2.7. Staining Cells 
Cells were incubated in blocking buffer (10% fetal bovine serum, Gibco, in PBS) for 1 h with 
gentle agitation, centrifuged for 3 min at 3600 RPM and the blocking buffer was removed. The cells 
were then incubated either in conjugated antibodies or in appropriate primary antibodies (i.e., WT1, 
AE1/AE3, CD45, CD34) with blocking buffer overnight at 4 °C with gentle agitation. Following 
primary antibody incubation, cells were centrifuged for 3 min at 3600 RPM and antibody aspirated. 
The cells were washed in PBS (Gibco) tween (0.2%) to remove any remaining antibody and 
centrifuged again for 3 min at 3600 RPM. In case of EpCAM, PBS was removed, and the cells were 
incubated in secondary antibody (Alexa Fluor 488 anti-mouse) diluted in blocking buffer (1:1000 v/v) 
for 1 hour with gentle agitation. From this step onwards, the cells were protected from light as the 
fluorophore conjugated to the secondary antibody is light sensitive. Further centrifugation for 3 
minutes at 3600 RPM was undertaken and the secondary antibody was removed. Following a wash 
in PBS tween and centrifugation, the PBS was removed, and the cells were resuspended in 99 μL 
Accumax (Innovative Cell Technologies, San Diego, CA, USA) to dissociate any cellular aggregates. 
1 μL of DRAQ5™ (Biostatus Ltd. Loughborough, UK) nuclear stain was added before visualisation 
on the ImageStream. All the data files were then analysed on the IDEAS software [9]. 
For the differential expression of AE1/AE3 and WT1 in SKOV3 and PEO1 cells, they were 
visualised under a Leica DM4000 microscope, x60. 
2.8. Imagestream™ 
To positively identify ovarian cancer CCs, pan-cytokeratin (AE1/AE3), CD45 (to exclude 
lymphocytes), WT1 (a nuclear/cytoplasmic stain specific to high grade serous ovarian/fallopian 
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tube/primary peritoneal cancer) and DRAQ5™ a general nuclear stain was all applied in different 
channels. EpCAM was applied to a subset of patients’ CCs to assess the value of EpCAM-related 
enumeration. CCs were identified and quantified using the IDEAs software. 
2.9. RNA Extraction/cDNA Synthesis 
If RNA extraction was not performed immediately, 0.5 mL of whole blood was added to 1.5 mL 
of RNAlater® (Life Technologies, Paisley, UK) in an Eppendorf tube, left at room temperature for up 
to 72 hours and stored at −80 °C until further use. Samples stored in RNALater were first defrosted 
from −20 °C at room temperature then centrifuged at 13,000 RPM for 1 min, followed by aspirating 
supernatant. RNA from blood samples were extracted using the Ribopure RNA extraction kit 
(Ambion, Fisher, UK) according to the manufacturer’s protocol. cDNA concentration was normalised 
using RNA concentrations determined using the NanoDrop (Thermo Scientific, Waltham, MA, USA). 
2.10. qPCR TATAA 
The CTC GrandPerformance panel (TATAA Biocenter, Göteborg, Sweden) was used for the 
quantification of ovarian cancer-associated gene expression using reverse transcription quantitative 
real-time PCR (qPCR). The isolated mRNA was reverse-transcribed into cDNA using GrandScript 
(TATAA Biocenter), pre-amplified in a multiplex-PCR using GrandMaster PreAmp (TATAA 
Biocenter) and quantified by single-plex qPCR using GrandMaster mix (TATAA Biocenter). Data 
analysis and classification of samples was done with the GenEx software (MultiD). 
2.11. Statistical Analysis 
All statistical tests were performed using GraphPad Prism® Software (GraphPad Software). 
Statistical analyses were performed using one-way ANOVA followed by Tukey’s Multiple 
Comparison Test or student’s t-test with significance determined at the level of P < 0.05. P values are 
indicated in graphs as follows; * P = 0.01–0.05, ** P = 0.001–0.009, and *** P < 0.0009. 
3. Results 
3.1. Identification of Ovarian Cancer Cells Mixed with Blood In Reconstruction Experiments Using 
AE1/AE3 and WT1 
Initial in vitro experiments were undertaken to ascertain staining of SKOV3 and MDAH274 
ovarian cancer cell lines with AE1/AE3 (CK+ antibodies), used widely in NHS histopathology 
laboratories for diagnosis [10]; as well as WT-1, which is an ovarian-specific stain (Figure S1A). 
Intensity of staining for AE1/AE3 confirmed the ability to differentiate cancer cells from white blood 
cells when SKOV3 and MDAH-2774 cells were spiked into 1 ml of healthy donor’s blood (Figure S1B). 
This procedure was repeated with the introduction of different quantities of SKOV3 and MDAH-
2774 cells to assess the efficiency of cell retrieval and loss when using AE1/AE3 and EpCAM. Table 
S1C shows a significantly reduced number of cultured SKOV3 and MDAH-2774 cells identified using 
EpCAM antibodies compared with AE1/AE3 (CK+). 
Furthermore, to elucidate any differences in the staining patterns between epithelial and 
mesenchymal phenotypes, we stained SKOV3 cells (exhibiting an intermediate mesenchymal (IM) 
phenotype) and PEO1 cells (exhibiting an epithelial (E) phenotype) with CK+ and WT1. We measured 
100 cells under the microscope, and all cells (100/100) stained positive for WT1. However, 88/100 of 
PEO1 (E) cells were stained CK+, whereas 41/100 SKOV3 (IM) were stained positive of CK at almost 
a 1:2 ratio (Figure S2). 
3.2. Validation of Blood Collection Tubes for CC Integrity 
Figure 2 details brightfield microscopy and nuclear definition (using DRAQ5™) of cells from 
aEOC NACT patient blood samples taken on Day 1 and analysed within 4 hours, and then at later 
time points (days 2–6) to assess the quality of cell preservation for the following tubes: EDTA, Cell-
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Free DNA Blood Collection Tube (Streck), PAXgene Blood DNA Tube (Qiagen) and Cell-Free DNA 
Collection Tube (Roche). The Roche was followed by PAXgene tubes preserved CCs for 6 days with 
reasonable morphology and reliable, reproducible nuclear staining. These tubes were used for all 
subsequent patient samples (Figure 2A–D). 
 
Figure 2. Circulating cell (CC) integrity over 6 days in EDTA tubes (A; 2 days), Streck tubes (B; 3 
days), PAXgene tubes (C, 6 days) and Roche (D, 6 days) as assessed by Imagestream™. Chanel 1: 
brightfield, Channel 5: DRAQ5™ nuclear staining (red). 
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3.3. Expression of AE1/AE3 (CK+), WT1, and CD45 in Enriched Blood Samples of Ovarian Cancer Patients 
Enriched blood samples were subjected to staining with AE1/AE3 (CK+), WT1, and CD45 to 
differentiate between ovarian CCs and WBCs. Examples include CK+, CK− and DRAQ5™+ (Figure 
3A–C); CK+ CD45−, DRAQ5™+ CCs (Figure 3D) in comparison with a CK− CD45+ DRAQ5™+ adjacent 
white blood cell (Figure 3E). Finally, CCs were also characterised using a WT1+, CD45− and, 
DRAQ5™+ staining (Figure 3F). 
Upon enumeration based on CK+, CD45− and DRAQ5™+, there was a significant increase in CCs 
in aEOC patients (n = 37; mean 547 CCs/mL of blood) in comparison with the number of cells staining 
negative for CK from whole blood from healthy female volunteers (n = 39, mean 47 CCs/mL of blood, 
Figure 4A; p = 0.040). 
A similar picture emerged, although with higher actual quantities, when CCs from HGSOC 
patients were selected based on WT1+, CD45− and DRAQ5™+ (n = 27, mean 2914) to healthy controls 
(n = 15, mean 667, Figure 4B; p = 0.039). ROC curves for all three measurements were significant, 
suggesting that this is of potential diagnostic value (Figure 4 C–D). We have also tried to correlate 
these findings with histopathological immunostaining data; from 22 (out of 29) reports for the WT1+ 
patients and 15 reports for the CK+ patients. In those reports analysed for the WT1+, 19 were found to 
be positive in both blood and tissue; whereas 2 were WT1+ in blood only and one was negative in 
blood but positive in tissue. All tissue samples were CK7 positive, whereas 14/15 blood samples were 
CK+ as well. Therefore, there is good correlation between histopathological findings and imaging 
flow-cytometry. 
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Figure 3. Circulating cells from an ovarian cancer patient blood sample based on staining in a scatter 
image generated by the Imagestream™. The micrograph shows images of single cells from ovarian 
cancer patients with: (A): positive staining for CK and nuclear staining (DRAQ5) identifying a 
potential circulating ovarian cell (CC), (B): negative staining for CK but positive for DRAQ5 
identifying a potential white blood cell (WBC), (C): combination of 2 potential WBCs (CK−) with a 
circulating ovarian CC (CK+); all three were stained positive for DRAQ5, (D): positive staining for CK, 
negative for CD45 and nuclear staining (DRAQ5) identifying a CC, (E): negative staining for CK, 
positive for CD45 and nuclear staining (DRAQ5) identifying a WBC, (F): a combination of 2 cells; one 
WT1 positive and one negative, both negative for CD45, but positive for nuclear staining (DRAQ5) 
identifying two potentially different CCs, but not WBCs. 
3.4. NACT, post-PDS, and Relapse Cohorts 
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The numbers of CK+ or WT1+ cells per mL of blood from patients in each of the three groups: 
NACT (n = 13 for CK+ and n = 11 for WT1+) versus post-PDS (n = 9 for both CK+ and WT1+) versus 
Relapse (n = 15 for CK+ and n = 7 for WT1+), are depicted in Figure 4 E,F and compared to healthy 
volunteers (n = 39 for CK+ and n = 15 for WT1+). 
Blood from patients with newly diagnosed stage IIIc/IV (and one stage II) ovarian cancer prior 
to any treatment (NACT) or following primary surgery only (post-PDS), contained significantly 
higher numbers of CK+/CD45−/DRAQ5™+ staining CCs as compared to healthy controls (p = 0.0049 
and p = 0.006 respectively). A similar, albeit non-significant trend was evident when controls were 
compared to patients after relapse (Figure 4E). The average CK+/CD45−/DRAQ5™+ CCs detected per 
ml of blood were: 47 for controls, 263 for NACT, 1155 for post-PDS, and 421 for relapse. 
When blood from patients was stained for WT1+/CD45−/DRAQ5™+, the average CCs detected 
per ml of blood were: 667 for controls, 4761 for NACT, 1718 for post-PDS, and 1548 for relapse. NACT 
patients had significantly higher numbers of WT1+/CD45−/DRAQ5™+ CCs compared to healthy 
controls (p = 0.0046). Notably, post-PDS patients had fewer WT1+ cells (mean 1718) than the NACT 
group (mean 4761; p = 0.08), possibly reflecting the substantial reduction in tumour mass at surgery 
(Figure 4F). 
 
Figure 4. Enumeration of CCs in controls against ovarian cancer (OC) patients: (A): CK+; *p < 0.05, and 
(B) WT1+, *p < 0.05. ROC curve analysis was used to measure sensitivity and specificity, an AUC of 
0.78 (***p < 0.0001) was calculated for CK+ (C), and an AUC of 0.82 (***p = 0.0006) was calculated for 
WT1+ (D). Enumeration of CCs in OC patients prior to any treatment at all (NACT), following primary 
surgery only (post-PDS), or relapse and comparison to healthy controls. (E): CK+/CD45−/DRAQ5™+ 
and (F) WT1+/CD45−/DRAQ5™+, **p < 0.001. 
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3.5. Correlation of CC with CA125 
Overall, CCs (WT1+/CD45−/DRAQ5™+) varied in broad alignment with serum CA125 response 
(Figure 5); for example, patient 14 had a similar drop in CCs and CA125 levels following the first 3 
treatments. However, when we performed correlation analysis (Pearson and Spearman) no apparent 
significance was reached. As it can be seen, patient 13 had adjuvant chemotherapy after primary 
surgery for stage IIB ovarian cancer and there was a good response that correlated with a drop in CC 
level, although no apparent change was noted for CA125 levels. A similar pattern was evident for 
patient 25, who received chemotherapy for first relapse ovarian cancer with a good clinical response. 
Patient 14, was a NACT patient that received 4 cycles of chemotherapy, followed by an unexpected 
50-day delay prior to interval surgery. It is evident that although CA125 remained stable, CCs rose 
in line with disease relapse/progression during this period. Patient 29 is a post-PDS (post-surgery) 
patient showing early relapse during adjuvant chemotherapy at 130 days, which was preceded by a 
rise in CC level at 60–70 days. If we had known this, we may well have withheld her chemotherapy 
after 2–3 cycles due to it being ineffective. CC levels decreased dramatically following treatment with 
letrozole and subsequent tamoxifen (relapse therapy). A one month follow up demonstrated a rapid 
surge of CCs concomitant with the diagnosis of brain metastases and relatively early death of this 
patient. 
 
Figure 5. Depiction of CC levels (blue markers) and CA125 (orange markers) for 4 aEOC patients over 
time (measured in days), in a cohort treated with chemotherapy (arrows). 
3.6. Changes in Sizes of CCs 
We have assessed the average size of CCs in our cohort of aEOC patients using IDEAS software 
(magnification x60) for CCs (CK+/WT1+/CD45−) and WBCs (CK−/WT1−/CD45+). The average sizes 
were: NACT-CK+ 7.33 μM, NACT-WT1+ 8.13 μM, post-PDS-CK+ 7.70 μM, post-PDS-WT1+ 8.00 μM, 
Relapse-CK+ 7.50 μM, and Relapse-WT1+ 8.13 μM. No significant changes in these sub-groups were 
apparent. However, when CCs were grouped based on CK+ and WT1+ staining, there was a subtle 
but significant difference: the average size of CK+ was 7.46 μM and of WT1+ it was 8.09 μM (Figure 
6). 
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CK+ + CD45+WT1  
Figure 6. Different sizes of WBCs (A: 8μM; B: 10μM), CK+ CCs (C: 7μM, D: 8.5 μM), WT1+ CCs (E: 
7μM; F: 8μM). (G): No apparent differences in size were detectable when combined CK+ and WT1+ 
CCs were measured and compared to controls. However, WT1+ CCs were larger compared to CK+ 
CCs; but not by a great margin (*P < 0.05). 
3.7. Relapse Cohort-Looking beyond CCs 
A 79-gene panel (TΑΤΑΑ Biocenter GrandPerformance assays) was used to explore whether 
RNA extracted from whole blood (i.e., including CCs and WBCs) would show a distinct molecular 
signature in a relapsed ovarian cancer cohort. For this part of the study, 25 samples were analysed 
from the 5 METRO-BIBF relapse aEOC patients (i.e., samples from sequential cycles of treatment for 
each of the 5 patients were also included) and compared to total blood RNA from 14 healthy controls 
(Figure S3). This revealed that in the METRO-BIBF patients 12 genes were up-regulated and 16 were 
down-regulated. Of the 12 upregulated genes VEGFA, HJURP, CCNE2, and RAD51 were also 
upregulated in the tissue of ovarian cancer patients according to in silico microarray data 
(Oncomine). Moreover, these genes were associated with worse overall survival (OS) in patients with 
aEOC (Kaplan Meier-Plot data) (Figure 7). 
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Figure 7. Oncomine analysis for VEGFA (A), HJURP (B), CCNE2 (C) and RAD51 (D) mRNA 
expression, using the Bonome ovarian dataset; Human Genome U133A Array (Normal benign 
controls (Lane 0) n = 10, and Ovarian Carcinoma (Lane 1) n = 185), demonstrate a significant 
upregulation for all four genes in the cancer cohort compared to controls: VEGFA (210512_s_at): (p = 
1.24 × 10−13; fold change = 1.670), HJURP (218726_at): (p = 9.10 × 10−10; fold change = 2.347), CCNE2 
(211814_s_at): (p = 5.80 × 10−6; fold change = 1.286) and RAD51 (205023_at): (p = 1.08 × 10−4; fold change 
= 1.475). Overall Survival (OS) plotted as a Kaplan Meier, shows poorer overall survival in the high 
expression group of OC patients for all 4 genes tested. More specifically: VEGFA (210512_s_at; (E): (p 
= 0.027, Low = 482 High = 1174), HJURP (218726_at; (F): (p = 0.015, Low = 459 High = 1197), CCNE2 
(205034_at; (G): (p = 0.00046, Low = 686 High = 970), and RAD51 (205023_at; (H): (p = 0.023, Low = 554 
High = 1102). 
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4. Discussion 
In this study, rather than attempting to ‘enrich’ our samples for circulating tumour cells (CTCs), 
we chose to examine the whole liquid biopsy following red blood cell lysis. By co-staining with CK 
and WT1 markers, and CD45 to exclude WBCs, we show that there are abundant non-haematopoietic 
CCs (CK+, WT1+ and CD45−) in patients with aEOC compared to healthy female controls. Detection 
of these CCs is reproducible, is reliably undertaken and can be informative. Previous studies may 
have underestimated the importance of CCs in patients with stage III/IV aEOC, which seem to 
represent a window in the microenvironment in which ovarian CTCs flourish. We show here that the 
size of CCs in ovarian cancer is not significantly different from the size of the rarer non-
haematological cells found in healthy controls, suggesting that efforts to identify ovarian CTCs based 
on size alone can be challenging and further studies needed to assess if treatments can impact on cell 
size. We have also shown, via a 79 gene panel, that 4 genes were found upregulated mirroring 
changes at tissue level, whereas EpCAM does not appear up-regulated in relapsed aEOC patients. 
Hence the important EMT derived CTC-population is also likely to be missed by currently used 
techniques involving EpCAM reliant enrichment [11]. 
A strength of flow cytometry is the ability to detect heterogeneity within a patient’s “CC-rich” 
sample, including sub-populations such as tumour cells and those of haematopoetic origin. However, 
flow cytometric assays are at risk of over-estimating rare events through non-specific antibody 
binding. Another false positive problem relates to antibody binding to soluble antigen forms. To 
mitigate these, we used DRAQ5™ staining for nuclear material to exclude apoptotic cells, cell debris, 
and platelet aggregates. Repeated gating and fluorescence compensation strategies may also 
augment inter-laboratory variability. Ideally >1 cell/μL is required to fulfil flow cytometric criteria 
with a coefficient variation of 10% [12]. 
A further limiting factor includes inter and intra-patient variability, described as differences in 
patient traits, characteristics, genetics and/or pharmacokinetics (including in some instances 
exposure to environmental influences) [13]. As highlighted earlier, the exact mechanism of CC 
shedding in malignancy is not well understood [5] and composition of CCs may differ from patient 
to patient, possibly in response to different biological and physiological states. Despite these potential 
limitations, we have shown that there are significantly lower numbers of CCs in patients with 
relapsed aEOC compared to newly presenting and immediately post-operative patients. In general, 
relapsed patients are not as systemically unwell as those at presentation, probably reflecting more 
timely interventions when we are already aware of the likelihood of relapse. Exploring the 
composition of the CCs in larger relapse patient cohorts is required to determine the relevance of this 
finding. 
We chose to explore the presence/absence of the Wilm’s Tumour protein, WT1 in CCs as 
nuclear/cytoplasmic expression of WT1 has 96% specificity and 100% sensitivity as a marker in serous 
tubal, ovarian, peritoneal cancer [14,15]. To the best of our knowledge, no other reports detail WT1 
expression on CCs in ovarian cancer and its potential to be a biomarker candidate for the 
identification of ovarian cancer CTCs. The median number of WT1+ CCs in our patient cohorts was 
2914 per mL whole blood, which is significantly more than the median of 667 per mL found in the 
healthy volunteers. Most patients in this study had confirmed WT1 positive tissue diagnoses of 
serous ovarian, tubal, or primary peritoneal cancer. Surprisingly, in two young female volunteers, 
we detected >4000 WT1+ CCs/mL which, however, is consistent with the presence of circulating 
endothelial cells found in females during the menstrual phase [16]. Indeed, in our study, these two 
controls with high detectable levels WT1 were of menstrual age (31 years). The average age of all 
healthy volunteers was 40 years (range 21–64 years), with 7 of them not having any WT1+ cells 
detected. Future studies using a larger age-matched control cohort will provide a better insight into 
how reliable this may be in premenopausal women in terms of indicating disease burden. 
We found a significantly higher number of cytokeratin-positive CCs amongst our patient 
population compared to healthy controls.  Techniques for concomitant membrane and nuclear 
staining are not sufficiently optimised yet to show how many of these are also WT1+ to confirm that 
these are tumour cells.  We postulate that a proportion of them might be circulating endothelial cells 
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(CECs). The presence of CECs has been recognised as a potential biomarker of vascular damage in 
many cancers including ovarian (500 CECs/mL) and renal cell (800 CECs/mL) cancers [17,18] [19]. 
Further work is on-going to confirm/refute this utilizing specific antibodies for endothelial cells (e.g., 
CD106, CD105, CD34, CD146). Preliminary evidence suggests presence of CD34+ (marker for CECs) 
cells in the blood of ovarian cancer patients (Figure S4). Another reason for the high numbers of CCs 
described in this study might be the absence of EPCAM enrichment, allows inclusion of cancer cells 
undergoing epithelial–mesenchymal transition (EMT), and not just those with pure epithelial 
phenotype. 
EMT is a fundamental developmental process during which epithelial cells lose their polarity 
and junctional architecture to become mesenchymal cells that are motile and contributes in tumour 
metastasis [20]. High grade serous ovarian cancer is believed to originate in the fimbrial ends of the 
fallopian tube where cells express a mesenchymal phenotype [21]. E-cadherin is highly expressed in 
primary ovarian carcinomas, but this is lost in the advanced stages; a hallmark of EMT. This is 
suggestive of EMT facilitating the invasive ovarian cancer phenotype [22]. In a more recent study, 
the authors argue that EMT is not complete in epithelial ovarian cancer and tumors can retain both 
phenotypes [23]. In terms of EMT events recorded in liquid biopsies, breast cancer CTCs express 
mesenchymal and epithelial markers, but mesenchymal cells are highly enriched in CTCs and are 
associated with disease progression [24]. To the best of our knowledge, there is no data relating to an 
EMT phenotype amongst CTCs of ovarian / fallopian tube origin, however during EMT transition 
there is a decrease in the expression of cytokeratins in ovarian cancer cells [25]. Therefore, we 
hypothesised that the difference in staining found here could be also attributed to ovarian CCs 
undergoing EMT. In a proof of principle experiment using SKOV3 cells (which exhibit an 
intermediate mesenchymal phenotype) and PEO1 cells (which exhibit an epithelial phenotype); we 
show that more PEO1 than SKOV3 cells stained positive with CK. 
Although, generally less sensitive than circulating-free DNA (cfDNA) [26,27] whole CC analysis 
can be performed at DNA, RNA (mRNA or micro-RNA) and protein level, providing further insight 
into the biology and microenvironment of cancer metastases. Contamination of CTCs with other non-
haematopoietic CCs, is little different to examining solid tumour tissue where cancer cells are within 
a microenvironment of normal and reactive stromal tissue. Our data from whole blood provides 
novel insights into the differential expression of genes from liquid biopsies but also poses certain 
limitations. For example, WBCs expression patterns vary with both inflammatory and nutritional 
states which are difficult to predict to allow accurate assessment of changing CC phenotypes. Future 
studies should concentrate on assessing gene expression of CCs only. However, current methods rely 
heavily on EPCAM dependent isolation techniques which will miss cells undergoing EMT transition. 
Future studies could capitalise on data available from databanks, although the current bioinformatic 
indexes (e.g., Oncomine, The Cancer Genome Atlas; TCGA) rely mostly on microarray/RNAseq data 
from tissue rather than from liquid biopsies. Exploration of the CC signatures of larger cohorts of 
aEOC patients, and correlation with paired diagnostic tissue, is planned to identify changes which 
will hopefully yield alternative therapeutic strategies or targets that can be harnessed for prognostic 
purposes. We suggest that this simple method of extracting CC-rich information has the potential for 
exploring part of the circulating microenvironment within the remit of nearside patient testing and 
rapid responses required for 21st century treatment. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Proof-of-
principle experiments using OC cell lines, Figure S2: changes in CK and WT1 staining depending on the 
epithelial/mesenchymal status, Figure S3: Gene expression data from whole blood, Figure S4: CD34+ (marker for 
CECs) cells in samples from two aEOC patients. 
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